Pharmaceuticals | Free Full-Text | Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.

Article

1

Pharmacy of Split-Dalmatia County, 21000 Split, Croatia

2

University Department of Health Studies, University of Split, 21000 Split, Croatia

3

Department of Toxicology and Pharmacogenetics, School of Medicine, University of Split, 21000 Split, Croatia

4

Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia

5

Department of Integrative Physiology, School of Medicine, University of Split, 21000 Split, Croatia

*

Author to whom correspondence should be addressed.

These authors contributed equally to this work.

Pharmaceuticals 2023, 16(5), 645; https://doi.org/10.3390/ph16050645 (registering DOI)

Received: 28 February 2023
/
Revised: 21 April 2023
/
Accepted: 23 April 2023
/
Published: 25 April 2023

Abstract

Cannabidiol (CBD) is a non-psychoactive cannabinoid, and available evidence suggests potential efficacy in the treatment of many disorders. DehydraTECH™2.0 CBD is a patented capsule formulation that improves the bioabsorption of CBD. We sought to compare the effects of CBD and DehydraTECH™2.0 CBD based on polymorphisms in CYP P450 genes and investigate the effects of a single CBD dose on blood pressure. In a randomized and double-blinded order, 12 females and 12 males with reported hypertension were given either placebo capsules or DehydraTECH™2.0 CBD (300 mg of CBD, each). Blood pressure and heart rate were measured during 3 h, and blood and urine samples were collected. In the first 20 min following the dose, there was a greater reduction in diastolic blood pressure (p = 0.025) and mean arterial pressure MAP (p = 0.056) with DehydraTECH™2.0 CBD, which was probably due to its greater CBD bioavailability. In the CYP2C9*2*3 enzyme, subjects with the poor metabolizer (PM) phenotype had higher plasma CBD concentrations. Both CYP2C19*2 (p = 0.037) and CYP2C19*17 (p = 0.022) were negatively associated with urinary CBD levels (beta = −0.489 for CYP2C19*2 and beta = −0.494 for CYP2C19*17). Further research is required to establish the impact of CYP P450 enzymes and the identification of metabolizer phenotype for the optimization of CBD formulations.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *